Green House Seeds Medical is the medical division of Green House Seeds. In the early 2000s, the company expanded into the medical field through the GH Medical division and related projects, such as Green House DRC in the Democratic Republic of the Congo (DRC). The medical division’s goal is to normalize cannabis for recreational and medical use, which ultimately contributed to its legalization in many countries, including 19 US states, Uruguay, and decriminalization in Europe.
GH Medical, founded by Arjan Roskam, focuses on the medical use of cannabis. The company collaborates with universities and clinics to develop cannabinoid-based medicines. In 2018, the GH Medical Congo Project was launched to produce medicines in the Democratic Republic of the Congo. By 2025, Green House had expanded to Thailand, Canada, and other regions, adapting genetics for large-scale production, including for medical purposes.
Green House Medical’s research focuses on genetics and cannabinoids. Through Strain Hunters, they have cataloged hundreds of strains, analyzing their active compounds (cannabinoids, terpenes) for treatment. In collaboration with GH Medical, Dutch doctors are identifying combinations for specific diseases, such as malaria, AIDS, respiratory infections, and diarrhea. In the Congo, GH Medical is researching local landraces and experimenting with them to produce low-cost medications. The company is also developing high-CBD strains for medical use, available in pharmacies, such as in the UK through MedBud.
Green House Seeds produces seeds for medical cannabis, but through GH Medical and Green House DRC, this production is directly translated into full-fledged medications. In the Democratic Republic of the Congo, they are developing cannabinoid medications based on local varieties that are inexpensive to grow and low-tech. The project includes clinical trials in collaboration with universities in Kinshasa and hospitals in the country. In other regions, such as Thailand and Canada, they produce oils, extracts, and products for the medical market. Arjan emphasizes that they produce medicines for people in places where the government fails.
Green House DRC is a key project in the Democratic Republic of Congo, launched in 2018. Arjan’s team owns plantations for growing local landrace cannabis and trains farmers and medical workers. They collaborate with the DRC’s ministries of agriculture, education, and health, as well as the University of Kinshasa. In 2020, the Congolese factory fed 250 families and 700 children, focusing on sustainable production. The plantations are used to preserve genetics and produce raw materials for medicines. Strain Hunters began with expeditions to Congo in the 2010s to search for cannabis varieties, which led to the establishment of the plantations.
In addition, Green House Medical has participated in a joint project with cannabis industry giant Canopy Growth Corporation and Organa Brands, known for its brands like O.penVAPE. This is a three-pronged partnership, rather than separate projects with each company. It focuses on the production and distribution of cannabis products, including medical ones, using Green House genetics and Organa Brands’ extraction technologies. The project is being implemented through a joint venture (JV) with Agripharm Corp., a licensed cannabis producer in Canada. The JV agreement was signed in November 2017, following the legalization of cannabis in Canada, where the recreational market opened in 2018. Previously, Agripharm was a wholly owned subsidiary of Canopy Growth, but under the JV, Canopy’s stake was reduced to 40%, Green House received 40%, and Organa Brands 20%.
The JV produces cannabis products based on Green House Seeds genetics, using CO₂ extraction technology for oils and infused products. The company’s product range includes:
Dry cannabis buds;
Cannabis oils and extracts
Other products (value-added), such as infused forms for consumption, capsules, vaporizers, and edibles.
Production is tailored for the medical and recreational markets, with a focus on medical applications: pain relief, anxiety relief, and infection relief. Agripharm is licensed to manufacture and sell up to $31.25 million annually.
Production takes place at Agripharm’s facility in Cremore, Ontario. Specific prices for JV products are not published, but general prices for cannabis products range from $6 to $12 per gram of dry cannabis. Oils and extracts range from $20–50 per ml or unit, depending on the CBD/THC concentration. Organa Brands vapes and extracts range from $30–80 per cartridge or vial. These prices vary by region, taxes, and regulations, and are current as of 2025.
The primary market is Canada (medical and recreational cannabis). JV also plans to expand into international markets: Germany, the UK, Australia… Green House and Organa products are distributed exclusively through Canopy in Canada, through Canopy’s online platforms (Tweed Main Street for medical cannabis), provincial retail chains, and wholesale to other licensed producers. In international markets, they are distributed through partners and pharmacies, such as Tweed in Germany.
Currently, there is no information on JV’s current revenue for 2025, but the project is considered a successful entry for Green House and Organa into the Canadian market, with potential for global growth. JV remains active, furthering Green House Medical’s global influence in cannabinoid medicine, although its focus has shifted to other Canopy initiatives after the 2020s.
In short, GH Medical continues to expand, and their overall commitment to medical cannabis—from genetics to local production—makes Green House Seeds a pioneer in the industry.